ATG16L1 and Crohn disease: Using ATG16L1 knockdown constructs in vitro that reduced the ATG16L1 protein levels to a similar degree as seen in homozygous ATG16L1 T300A carriers (Murthy et al., 2014), we aimed to elucidate part of the mechanism that makes homozygous carriers prone to developing Crohn's disease.